Evelo Biosciences(US:EVLO)2023-03-16 15:24Financial Data and Key Metrics Changes - The company raised $79.2 million through a Registered Direct Offering in May 2022 and refinanced $45 million debt in December 2022, indicating strong financial maneuvering [26][60]. - The clinical responses for EDP1815 showed that 45% of patients maintained a PASI-50 response or greater after treatment, demonstrating the durability of clinical effects [50]. Business Line Data and Key Metrics Changes - EDP2939 has begun dosing in patients with moderate psoriasis, with clear safety and tolerability observed in healthy volunteers [49][60]. - The Phase 2 study for EDP1815 in atopic dermatitis did not meet primary endpoints due to a high placebo response, with results from the fourth cohort expected in Q2 2023 [60]. Market Data and Key Metrics Changes - The company is exploring the potential of EDP1815 in the Phase 2 atopic dermatitis study, which has faced challenges due to an unusually high placebo rate [60]. - EDP2939 is positioned as a significant advancement in the treatment of systemic inflammatory diseases, with expectations for improved clinical activity [62]. Company Strategy and Development Direction - The company aims to advance EDP1815 into Phase 3 trials, contingent on financing availability, while also prioritizing EDP2939 [60]. - Ongoing discussions for partnerships are focused on both EDP1815 and EDP2939, with the goal of securing a partnership within the year [33]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of EDP2939 to drive greater efficacy than EDP1815, based on preclinical data [25][36]. - The current environment for small-cap biotech is challenging, but the company sees significant opportunities for advancement in its clinical programs [29]. Other Important Information - The company has ruled out mix-ups in supplier drugs as a cause for high placebo responses in clinical trials, indicating thorough investigation into trial integrity [38]. - The safety review for EDP2939 confirmed that it meets safety and tolerability criteria, allowing progression to Phase 2 trials [28]. Q&A Session Summary Question: What gives confidence to move forward with the lower dose in psoriasis patients? - Management is working through key components related to dosing and has confidence based on preclinical data [39][41]. Question: What is the efficacy hurdle for the AD data expected in Q2? - The company is looking for around 40% EASI-50 response in active patients with a placebo separation of 15% [19]. Question: Are there any modifications made to manage the high placebo response in the atopic derm trial? - Management confirmed that the cohort was locked, and no modifications could be made [65].